Browse by author
Lookup NU author(s): Dr Mark Hudson,
Dr Stuart McPhersonORCiD,
Professor Alastair BurtORCiD,
Professor Margaret Bassendine
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
A 2-center retrospective analysis was performed in 60 patients undergoing liver transplantation for hepatitis C virus (HCV)related disease (cyclosporine in 20, tacrolimus in 40). Mean (±SEM) follow-up was 23.6 ± 22.5 and 22.3 ± 13.7 months in patients receiving cyclosporine or tacrolimus, respectively. Clinically indicated biopsies were performed in 15/20 cyclosporine patients (75%) and 22/40 tacrolimus patients (55%; P = .17). The Ishak fibrosis score was significantly lower in cyclosporine-treated patients versus tacrolimus-treated patients (mean 1.7 ± 0.4 vs 3.1 ± 0.4; P = .023), as was percentage of fibrosis grade Ishak <4 (7% vs 41%; P = .028). The mean time to moderate fibrosis (Ishak score <3) was 38.2 ± 15.1 months in cyclosporine patients (4/15) and 23.5 ± 12.6 months in tacrolimus patients (14/22); the difference was not statistically significant (P = .09). This retrospective study suggests that cyclosporine-based immunosuppression is associated with less severe hepatic fibrosis in HCV-positive liver transplant recipients compared with tacrolimus-based regimens, but a larger prospective comparative trial is necessary to confirm these findings. © 2010 Elsevier Inc. All rights reserved.
Author(s): Van Der Laan L, Hudson M, McPherson S, Zondervan P, Thomas R, Kwekkeboom J, Lindsay A, Burt A, Kazemier G, Tilanus H, Bassendine M, Metselaar H
Publication type: Article
Publication status: Published
Journal: Transplantation Proceedings
Print publication date: 17/12/2010
ISSN (print): 0041-1345
Publisher: Elsevier Inc
Altmetrics provided by Altmetric